Cerebral vasospasm after subarachnoid haemorrhage
Subarachnoid haemorrhage (SAH), most often from a ruptured intracranial aneurysm, can trigger intense vasoconstriction of cerebral arteries. Reduced blood flow may cause delayed cerebral ischaemia, a major source of disability after the bleed. Prevention begins in the first hours, while surveillance and treatment remain essential through the second week.
Vasospasm is not the initial haemorrhage. It usually develops over several days, often between days three and fourteen, and may be clinically silent. Narrowed arteries can cause infarction, but symptoms also reflect haemorrhage, hydrocephalus, seizure, infection or metabolic disturbance. Accurate assessment therefore matters as much as calendar-based monitoring.
Care is multidisciplinary: neurosurgery, neurology, neurocritical care, radiology and nursing share the workload, with pharmacy and rehabilitation input. Nimodipine is the principal preventive drug; induced hypertension and endovascular rescue are reserved for suspected symptomatic ischaemia. Evidence supports staged care rather than routine escalation for every patient.
Most vasospasm is managed in intensive care, but pathways differ between metropolitan and rural services. Australian ambulance networks, emergency routes and access to interventional neuroradiology shape local care. This review focuses on adult aneurysmal SAH and translates current evidence into practical prevention, diagnosis and treatment decisions.
Why delayed cerebral ischaemia matters
Inflammatory mediators, endothelial injury and smooth-muscle contraction narrow arteries in the circle of Willis and nearby vessels. Hypovolaemia, hypoxia, hypotension, fever or poor glucose control can worsen the effect. Angiography shows arterial narrowing, but the clinically important outcome is whether blood flow falls below the level needed to sustain brain tissue.
The dangerous period is usually days three to fourteen after SAH, with peak risk around days five to seven. Delayed cerebral ischaemia can produce new weakness, aphasia, confusion or reduced consciousness, and infarction may cause lasting deficits. Severity at presentation, rebleeding and early brain injury also affect recovery.
Families should receive clear explanations about why monitoring continues after the main bleed has been treated. For non-clinical information that can complement discharge and rehabilitation discussions, Near the Lighthouse is a useful companion resource. The treating team remains the source of individual advice about prognosis, medication and warning signs.
Recognising the warning signs
Clinical deterioration after SAH should never be dismissed as anxiety or routine ward fatigue. A new focal deficit, reduced consciousness, new troublesome headache, vomiting or seizure may signal delayed cerebral ischaemia, but none is specific. Staff should be told immediately, and medical review should document power, speech, pupils and any change from the previous examination.
Important mimics include rebleeding, subdural haematoma, cerebral oedema, hydrocephalus, hyponatraemia, sepsis, seizures and medication effects. Imaging and blood tests may be needed together because complications can coexist. Fever and pain need attention because they can lower cerebral perfusion or increase oxygen demand.
For a patient at home after SAH, sudden neurological symptoms or rapidly worsening headache warrant calling Triple Zero (000) and following the dispatcher’s instructions, rather than arranging a routine GP appointment or driving themselves. After discharge, families often notice subtle change first; written escalation plans can reduce delays across Australian cities and regional towns.
Preventing cerebral vasospasm
Nimodipine is standard preventive therapy for adults with aneurysmal SAH. A common regimen is 60 mg enterally every four hours for 21 days, started early and ideally within four days of the bleed. Its calcium-channel-blocking action reduces delayed cerebral ischaemia but does not reliably reverse established narrowing. Blood pressure and adverse effects should be checked before each dose, with adjustment or withholding if clinically necessary.
The second cornerstone is euvolaemia. Clinicians should replace ongoing losses and avoid both hypovolaemia and deliberate prophylactic hypervolaemia, which can cause pulmonary oedema without preventing ischaemia. Sodium and fluid balance require close review, especially with hyponatraemia. Blood-pressure targets are individualised: severe hypertension needs control, but hypotension can reduce perfusion and should be corrected promptly.
Routine statins, magnesium sulphate, prophylactic angioplasty and prophylactic induced hypertension have not shown consistent clinical benefit and should not replace established care. Seizure prophylaxis is selected according to seizure risk, not used as vasospasm treatment. Anticoagulants or thrombolytics are not indicated for vasospasm without a separate reason, because anticoagulation can worsen haemorrhage risk.
Longer-term risk reduction includes treating hypertension, stopping smoking, limiting alcohol and avoiding cocaine or sympathomimetic drugs. In Australia, some over-the-counter decongestants can affect blood pressure or heart rhythm, so medication reviews should include them. The Therapeutic Goods Administration, Pharmaceutical Benefits Scheme and hospital formularies shape prescribing and supply.
Confirming the cause
Repeated neurological examinations are paired with CT angiography when deterioration suggests arterial narrowing. Transcranial Doppler can track flow velocity, while CT perfusion estimates haemodynamic compromise. These tools identify affected territory and severity, but each has limitations involving movement, bone artefact, vasopressors and individual anatomy.
Digital subtraction angiography remains the reference standard and is usually required before endovascular intervention. It directly shows the extent of vasospasm but is invasive, with a small risk of stroke or vessel injury. At centres without overnight angiography, a metropolitan neurointerventional team can join by video while transfer is arranged.
No single test replaces clinical judgement. The critical step is rapid correlation of new symptoms, examination, imaging and laboratory results with senior neurology and neurosurgical input, so treatable complications are not missed and harmful responses are avoided.
Treating established vasospasm
Treatment of symptomatic delayed cerebral ischaemia starts with correction of contributing factors: restore adequate volume, treat fever and pain, maintain oxygenation, check glucose and sodium, and review sedatives or antihypertensives. These measures protect perfusion while the team confirms the cause. Fluid restriction is not automatic, because hypovolaemia can worsen brain perfusion.
Once symptomatic ischaemia is strongly suspected, induced hypertension may improve cerebral blood flow through narrowed arteries. It is a monitored, titrated ICU intervention rather than a blanket prescription, and it should follow correction of hypovolaemia and exclusion of haemorrhage or cardiac contraindications. The target and duration are individualised, with frequent neurological and cardiovascular assessment.
When improvement is inadequate or sustained hypertension is unsafe, endovascular rescue may be considered. Intraluminal angioplasty can open selected narrowed arteries; intra-arterial vasodilators such as verapamil or milrinone are sometimes used as adjuncts. Both carry risks, including vessel injury and haemorrhage, and use depends on anatomy, expertise and urgency.
Other problems require parallel treatment. Hyponatraemia may reflect syndrome of inappropriate antidiuretic hormone secretion or cerebral salt wasting, which need different fluid strategies; severe seizures may need anti-epileptic therapy. There is no role for anticoagulation or thrombolysis aimed at the spasm itself, and pneumonia, urinary sepsis or myocardial ischaemia must not obscure the neurological cause.
Australian care pathways and recovery
Australia’s major neurovascular hubs in Melbourne, Sydney, Brisbane and Perth provide 24-hour neurosurgical, stroke and neurocritical care, while regional hospitals manage initial stabilisation and transfer. Retrieval priorities, ambulance transport and local specialist coverage determine the route. Rural and remote patients may need road or air transfer, teleconsultation and careful consent across institutions.
Medicare supports public hospital treatment and general-practice care, while the Pharmaceutical Benefits Scheme and hospital formularies shape medication access. Complex endovascular work is concentrated in tertiary centres and selected private neurointerventional services, raising questions about referral, private insurance and travel costs. Patients need clear information about expected transfers.
Recovery may involve fatigue, memory problems, emotional distress and difficulty returning to work or driving. Licensing questions differ across states and territories, so restrictions should be documented and checked against current local road rules. Clinical records and teleconference discussions must also comply with the Privacy Act 1988 and Australian Privacy Principles, including appropriate consent and secure handling of health information.
Keeping up with evidence and regulation is difficult for busy teams. Clinicians can follow clinical news updates for relevant medical developments and use open peer discussion to compare local protocols with wider practice.
Weighing options and practical evidence
Preventive and therapeutic strategies answer different questions. Nimodipine and careful volume management reduce the likelihood or impact of delayed ischaemia; induced hypertension and endovascular treatment respond to established symptomatic disease. The strongest evidence supports nimodipine, early specialist care and prompt reassessment. Rescue therapies have less uniform evidence but may be essential during neurological deterioration.
Decision-making should combine the examination, vessel anatomy, time course, haemodynamic state and the patient’s goals. Raising blood pressure can be unsafe in severe cardiac disease, while withholding escalation may allow irreversible infarction. Documenting why a strategy was chosen, including risks accepted, improves continuity between shifts and communication with families.
| Strategy | Typical role | Main evidence | Important limitation |
|---|---|---|---|
| Nimodipine | Standard prophylaxis after aneurysmal SAH | Reduces delayed cerebral ischaemia | Requires adherence and blood-pressure checks; does not reverse established spasm |
| Euvolaemia | Baseline fluid and blood-pressure support | Helps prevent hypovolaemia-related hypoperfusion | Over-expansion can cause pulmonary oedema |
| Induced hypertension | Selected symptomatic ischaemia after exclusions | May increase flow through narrowed circulation | Cardiac, haemorrhagic and renal risks require intensive monitoring |
| Angioplasty and intra-arterial drugs | Refractory or high-risk symptomatic vasospasm | May produce rapid angiographic or clinical improvement | Invasive, with vessel injury and bleeding risk; evidence mainly observational |
| Statins, magnesium and prophylactic angioplasty | Considered only for selected indications | Inconsistent clinical benefit | Not substitutes for established preventive or rescue care |
Access, monitoring and timing influence every option’s practical benefit. An effective preventive drug can fail if given late, while rescue treatment without a clear clinical trigger adds risk without benefit. Guidelines should guide but not dictate individual care.
Clinicians, students and families can act by subscribing to Thamburaj for new clinical insights, registering for the open peer forum, and sharing this article with an affected household. Online material should support, not replace, urgent medical assessment.
Before discharge, ask for a written plan covering nimodipine timing, blood-pressure and fluid instructions, warning symptoms, follow-up imaging, rehabilitation and driving. Record the neurosurgical and neurological contacts the family may need after leaving hospital.